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Effects of an Antenatal Dietary Intervention on Maternal
Anthropometric Measures in Pregnant Women with Obesity
Jodie M. Dodd1,2,3, Lavern M. Kannieappan1,2, Rosalie M. Grivell1,2,3, Andrea R. Deussen1,2, Lisa J. Moran1,2,
Lisa N. Yelland1,2,4,5, and Julie A. Owens1,2
Objective: The effect of providing antenatal dietary and lifestyle advice on secondary measures of mater-
nal anthropometry was evaluated and their correlation with both gestational weight gain and infant birth
weight was assessed.
Methods: In a multicenter, randomized controlled trial, pregnant women with BMI of 25 kg/m2 received
either Lifestyle Advice or Standard Care. Maternal anthropometric outcomes included arm circumference,
biceps, triceps, and subscapular skinfold thickness measurements (SFTM), percentage body fat (BF),
gestational weight gain, and infant birth weight. The intention to treat principles were utilized by the
analyses.
Results: The measurements were obtained from 807 (74.7%) women in the Lifestyle Advice Group and
775 (72.3%) women in the Standard Care Group. There were no statistically significant differences identi-
fied between the treatment groups with regards to arm circumference, biceps, triceps, and subscapular
SFTM, or percentage BF at 36-week gestation. Maternal anthropometric measurements were not signifi-
cantly correlated with either gestational weight gain or infant birth weight.
Conclusions: Among pregnant women with a BMI of 25 kg/m2, maternal SFTM were not modified by
an antenatal dietary and lifestyle intervention. Furthermore, maternal SFTM correlate poorly with both
gestational weight gain and infant birth weight.
Obesity (2015) 23, 1555–1562. doi:10.1002/oby.21145
Introduction
Overweight and obesity represent a considerable disease burden dur-
ing pregnancy, with half of all women having a body mass index
(BMI) of 25 kg/m2 on entering pregnancy (1,2). The literature
highlights the associations between maternal obesity and an
increased risk of adverse outcomes for both women and their
infants, all of which increase as maternal BMI increases (3,4). Addi-
tionally, there is evidence of a persisting longer-term health legacy,
maternal obesity being associated with an increased risk of high
infant birth weight (4) and, in turn, subsequent obesity (5,6).
The US Institute of Medicine has summarized the observational lit-
erature relating to maternal gestational weight gain, reporting aver-
age total weight gains between 10 and 15 kg (7). However, there
was considerable interindividual variation with many women,
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particularly those with a BMI of 25 kg/m2, exceeding this average
(7). Nevertheless, current recommendations suggest a weight gain of
7.0-11.5 kg for women with a BMI of 25-29.9 kg/m2 and 5.0-9.0 kg
for women with a BMI of 30 kg/m2 or more (7).
In nonpregnant individuals, there is a clear relationship between
measured weight gain and adiposity gain. In contrast, gestational
weight gain while used as a surrogate marker of adiposity (8) in fact
reflects a combination of maternal fat deposition, pregnancy-related
plasma volume expansion, peripheral edema, placental mass, fetal
mass, and amniotic fluid volume (9). Furthermore, from a practical
perspective, determining the relative contribution of each of these
individual components is extremely difficult (9).
Although a number of techniques have been proposed to differenti-
ate between the various components and more accurately determine
maternal adiposity, all have limitations, particularly during preg-
nancy. Although BMI correlates well with the markers of adult
health and disease risk, it does not differentiate between adipose and
lean tissue mass or between maternal and fetal contributions to
weight gain. Bioimpedance analysis, dual-energy X-ray absorptiome-
try, computed tomography, magnetic resonance imaging, and three
or four compartment model assessments all more accurately deter-
mine adipose and lean tissues. Limitations include the lack of differ-
entiation between maternal and fetal tissues, exposure to ionizing
radiation (9,10), and lack of portability and expense (9,11,12), all of
which make these assessments impractical to carry out on a large
scale.
In contrast, skinfold thickness measurements (SFTM) have been pro-
posed for use in pregnancy as they are reproducible with specific
training and adherence to defined protocols, and through the mea-
surement of between three and seven body sites, they allow estima-
tion of body fat (BF) percentage (9,13). In particular, use of the
biceps, triceps, and subscapular sites allows the evaluation of
pregnancy-related changes in adipose tissue that are more independ-
ent of fetal growth (9,14). Although some have suggested that
SFTM lack reproducibility (15), we have documented acceptable
interobserver variability from a population of pregnant women with
a BMI of 25 kg/m2 (16).
Observational studies involving lean pregnant women suggest depo-
sition of adipose tissue in the second trimester of pregnancy with
subsequent mobilization in late gestation (17-20). It is unclear if this
is also the case among women with a BMI of 25 kg/m2, who have
increased reliance on lipid metabolism during pregnancy (21). Simi-
larly, the relationship between changes in adipose tissue deposition
and SFTM, particularly among women with a BMI of 25 kg/m2
(19,22), and any correlation with either gestational weight gain or
infant birth weight (23,24) remain to be determined.
We have reported the primary findings of the LIMIT randomized
trial evaluating the provision of antenatal dietary and lifestyle advice
to women with a BMI of 25 kg/m2, which indicate a significant
18% relative risk reduction in infant birth weight of >4 kg (25),
mediated by improvements in maternal diet and physical activity
(26). The aims of this study were twofold. First, we report the effect
of providing antenatal dietary and lifestyle advice on the measures
of maternal SFTM; and second, we assess the correlation between
maternal SFTM and both gestational weight gain and infant birth
weight.
Methods
Study design
We conducted a multicenter, randomized trial involving three mater-
nity hospitals across Adelaide, South Australia. The methods (27)
and primary findings (25,26,28) from the LIMIT randomized trial
have been reported, and the trial registered on the Australian and
New Zealand Clinical Trials Registry (ACTRN12607000161426).
Inclusion and exclusion criteria
Women with BMI of 25 kg/m2 and singleton pregnancy at 1010-
2010 weeks gestation were eligible.
Trial entry
All women presenting for antenatal care had their height and weight
measured, and BMI calculated at the first antenatal appointment.
Eligible women were presented with written information, and all
women provided written informed consent.
Randomization, masking, and group allocation
Randomization occurred by telephoning the central randomization
service, which used a computer-generated schedule, with balanced
variable blocks. Stratification occurred for parity (0 vs. 1/more),
BMI at antenatal booking (25-29.9 vs. 30 kg/m2), and collaborat-
ing center. Women were randomized to either “Lifestyle Advice” or
“Standard Care.”
Treatment schedules
Lifestyle Advice Group. Women randomized to receive Lifestyle
Advice participated in a comprehensive dietary and lifestyle interven-
tion over the course of pregnancy that included a combination of die-
tary, physical activity, and behavioral strategies, delivered by a
research dietician and trained research assistants (25,26). Within 2
weeks of randomization, women attended a planning session with a
research dietician, during which a detailed dietary and physical activ-
ity history was obtained (25,26). Women were provided with individ-
ualized dietary advice consistent with current Australian standards, to
maintain a balance of carbohydrates, fat, and protein, to reduce intake
of foods high in refined carbohydrates and saturated fats, while
increasing intake of fiber, and promoting consumption of two serv-
ings of fruit, five servings of vegetables, and three servings of dairy
each day. Physical activity advice focussed on the benefits of exercise
in pregnancy, and tips to increase incidental activity and walking.
Women were encouraged to set achievable goals for change, and to
self-monitor their progress. This information was reinforced during
subsequent inputs provided by the research dietician (at 28-week ges-
tation) and trained research assistants (via telephone call at 22-, 24-,
and 32-week gestation and a face-to-face visit at 36-week gestation).
Standard Care Group. Women receiving Standard Care contin-
ued their pregnancy care according to local hospital guidelines,
which did not include routine provision of advice related to diet,
exercise, or gestational weight gain.
Study end points: maternal anthropometry
At trial entry and 36-week gestation, maternal anthropometric meas-
ures were obtained (16), using a standardized protocol on the right-
hand side of the woman’s body (13).
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Arm circumference. With the woman standing with her arms
relaxed at her side, the midpoint between the most superior and the
lateral point of the acromion border and the most proximal and lat-
eral border of the head of the radius was identified and the circum-
ference measured using the crosshand technique, with the reading
taken at eye level with constant tension applied to the tape (13,16).
Two separate marks were made on the woman’s arm on the most
anterior point of the biceps and the most posterior point of the tri-
ceps, to assist in locating these skinfold landmarks (13,16).
Skinfold thickness measurements. SFTM were obtained using
Harpenden Callipers, with a dial graduation of 0.2 mm and meas-
uring range 0-80 mm, which was viewed at 908 to avoid errors of
parallax. Two measurements were taken, with a third measurement
obtained if the difference was >7.5% (13,16). The measurements
were recorded to the nearest 0.1 mm and reported as the average of
two measurements or the median of 3 (13,16).
Biceps. With the woman standing relaxed, with arms at her side,
the biceps skinfold was visualized, and the site located on the ante-
rior surface of the arm, in line with the mid-arm point (as marked
when the arm circumference was measured) and parallel to the long
axis (13,16).
Triceps. With the woman standing relaxed and her arm slightly
pronated, the triceps skinfold was visualized from the posterior sur-
face of the arm, in line with the mid-arm point in the horizontal
plane (as marked when the arm circumference was measured), and
parallel to the long axis (13,16).
Subscapular. The inferior angle of the scapula was palpated, and
a site marked 2 cm and 458 inferiorly (13,16). If required, the
woman was asked to reach behind her back with her right arm to
better expose the scapula (13,16).
BF percentage. Using the following equation for use with preg-
nant women with a BMI of 25 kg/m2, percentage BF was calcu-
lated, where SFTM were reported in millimeters, and arm circumfer-
ence and height were reported in centimeters (16).
Figure 1 Flow of participants.
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BF%5 12.71 0.457 (Triceps SFTM)1 0.352 (Subscapular
SFTM)1 0.103 (Biceps SFTM)2 0.057 (Height)1 0.265 (Arm
circumference).
Gestational weight gain. Gestational weight gain was calculated
as the difference in measured weight by subtracting the weight
obtained at trial entry from the weight obtained at 36 weeks of ges-
tation. Weight was obtained with the woman in light clothing and
without shoes, using digital scales, and recorded to the nearest
0.1 kg. Height was obtained without shoes, using a wall-mounted
stadiometer, and recorded to the nearest 0.5 cm.
Analysis and reporting of results
The analyses were performed on an intention to treat basis, with
women analyzed according to their randomized treatment group.
Women were included in the analysis if they consented to anthropo-
metric measurements being taken, and did not withdraw consent to
use their data or have a miscarriage, or termination of pregnancy.
The outcomes considered were the anthropometric measurements
taken at 36-week gestation, and both the total and the average
weekly change in anthropometric measurements between trial entry
and 36 weeks. The analyses were performed using linear regression
models to determine the effect of treatment group on each outcome,
adjusting for center, parity, BMI category, age, socioeconomic sta-
tus, the anthropometric measurement at trial entry, and either the
actual gestational age at measurement (for anthropometric measure-
ments at 36 weeks), or the time between measurements (for changes
in anthropometric measurements). Exploratory analyses were con-
ducted to assess whether the effect of treatment varied by BMI cate-
gory (overweight vs. obese), by including an interaction between
treatment group and BMI category in the regression model.
TABLE 1 Baseline demographic and anthropometric measurements at trial entry
Characteristic Lifestyle Advice, N5872a Standard Care, N5 835a Total, N51,707a
Maternal age (years)b 29.6 (5.3) 29.6 (5.5) 29.6 (5.4)
Gestational age at entry (weeks)c 14.1 (12.0-16.9) 14.3 (12.0-17.0) 14.1 (12.0-17.0)
BMI (kg/m2)c 31.0 (28.0-35.9) 31.1 (27.6-35.8) 31.0 (27.8-35.8)
BMI categoryd
25.0-29.9 365 (41.9) 360 (43.1) 725 (42.5)
30.0-34.9 249 (28.6) 238 (28.5) 487 (28.5)
35.0-39.9 167 (19.2) 135 (16.2) 302 (17.7)
40.0 91 (10.4) 102 (12.2) 193 (11.3)
Public patientd 855 (98.1) 814 (97.5) 1669 (97.8)
Weight (kg)b 88.4 (17.0) 88.3 (17.6) 88.3 (17.3)
Height (cm)b 164.9 (6.6) 164.9 (6.5) 164.9 (6.5)
Raced
Caucasian 789 (90.5) 764 (91.5) 1553 (91.0)
Asian 19 (2.2) 21 (2.5) 40 (2.3)
Indian 30 (3.4) 27 (3.2) 57 (3.3)
Other 34 (3.9) 23 (2.8) 57 (3.3)
Smokerd 110 (12.6) 93 (11.1) 203 (11.9)
Nulliparousd 354 (40.6) 358 (42.9) 712 (41.7)
Index of socio economic disadvantagee
Unknown 1 (0.1) 1 (0.1) 2 (0.1)
Quintile 1 (most disadvantaged) 262 (30.0) 240 (28.7) 502 (29.4)
Quintile 2 207 (23.7) 212 (25.4) 419 (24.5)
Quintile 3 133 (15.3) 125 (15.0) 258 (15.1)
Quintile 4 126 (14.4) 133 (15.9) 259 (15.2)
Quintile 5 (least disadvantaged) 143 (16.4) 124 (14.9) 267 (15.6)
Arm girth at trial entry (cm)b 35.5 (4.4) 35.4 (4.4) 35.5 (4.4)
Biceps SFTM at trial entry (mm)b 18.2 (7.5) 17.4 (6.9) 17.8 (7.2)
Triceps SFTM at trial entry (mm)b 27.8 (7.3) 28.4 (7.4) 28.1 (7.4)
Subscapular SFTM at trial entry (mm)b 28.8 (9.1) 29.4 (9.7) 29.1 (9.4)
Percent BF at trial entryb 37.4 (7.2) 37.7 (7.5) 37.6 (7.3)
GA at trial entry measurement (weeks)c 17.0 (14.3-19.9) 18.9 (14.9-20.4) 17.6 (14.6-20.3)
aIncludes all women randomized who did not withdraw consent to use their data and who had anthropometric measurements taken at baseline.
bMean and standard deviation.
cMedian and interquartile range.
dNumber and percentage.
eSocio economic index as measured by SEIFA.
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Statistical significance was assessed at the two-sided P< 0.05 level
and no adjustment was made for multiple comparisons. Pearson’s
correlation coefficients were calculated to measure the strength of
association between anthropometric measurements, total gestational
weight gain, and infant birth weight. All analyses were performed
using SAS v9.3 (Cary, NC, USA).
Sample size
The sample size of 2,180 women was predetermined based on the
primary outcome, large for gestational age infant (25).
Ethics
Ethics approval was provided by the Women’s and Children’s Local
Health Network Human Research and Ethics Committee at the
Women’s and Children’s Hospital, the Central Northern Adelaide
Health Service Ethics of Human Research Committee (Lyell McE-
win Hospital) and the Flinders Clinical Research Ethics Committee
(Flinders Medical Centre).
Results
Between June 2008 and December 2011, 2,212 women were
randomized, with 1,108 allocated to receive Lifestyle Advice, and
1,104 Standard Care. There were 2,154 women (1,080 Lifestyle
Advice; 1,072 Standard Care) available for inclusion in the analyses,
after excluding women who withdrew consent to use their data (ten
women) or had a miscarriage, or termination of pregnancy (50
women) (25). The measurements were obtained from 872 (80.7%)
women at trial entry, and 807 (74.7%) at 36 weeks of gestation in
the Lifestyle Advice Group, and 835 (77.9%) women at trial entry,
and 775 (72.3%) at 36 weeks of gestation in the Standard Care
Group, who were included in the analyses (Figure 1). The median
time between trial entry and 36-week gestation measurements was
18.4 weeks (interquartile range, 16.0-21.6 weeks). Baseline demo-
graphic and anthropometric measures of the women who had their
measurements obtained were similar between treatment groups
(Table 1) and their clinical characteristics similar to the full random-
ized groups (data not shown) (25).
There were no statistically significant differences between those
women receiving Lifestyle Advice and those receiving Standard
Care, with regards to arm circumference, and biceps, triceps, and sub-
scapular SFTM obtained at 36-week gestation (Table 2). There was
no difference observed between groups in the change in these meas-
urements from baseline to 36 weeks, when expressed either as total
change, or as an average weekly change to account for variation in
gestational age at measurement. The calculated percentage BF at 36-
week gestation did not significantly differ between the two treatment
groups (37.666 7.12% Lifestyle Advice vs. 37.256 7.02% Standard
Care; adjusted mean difference 0.48; 95% CI 20.01 to 1.00;
P5 0.07), with no difference observed in the change in percentage
BF expressed either as total change across gestation, or as average
weekly change. There was no evidence to suggest that the interven-
tion effect was modified by maternal BMI category (data not shown).
All SFTM and arm circumference measurements were not significantly
correlated with either gestational weight gain or infant birth weight,
correlation coefficients ranging between20.239 and 0.111 (Table 3).
Discussion
Our randomized trial is the largest reported to date evaluating the
effects of an antenatal lifestyle intervention for women with a BMI of
25 kg/m2 during pregnancy on maternal anthropometric measures,
and it utilized robust methodology. Our findings indicate that provid-
ing an intervention during pregnancy was not effective in reducing
gestational weight gain (25) or maternal measures of peripheral adi-
pose tissue deposition. Nor was there any effect on maternal percent-
age BF, with no evidence to suggest this differed among women with
a BMI of 25–29.9 kg/m2 and 30 kg/m2. Furthermore, SFTM and
anthropometric measures were not significantly correlated with either
gestational weight gain or infant birth weight.
Our study has a number of strengths, including the large sample size
of pregnant women with a BMI of 25 kg/m2, which has been a
TABLE 3 Correlations between maternal morphology measurements at trial entry and 36-week gestation, gestational weight
gain, and infant birth weight
Pearson’s correlation coefficients
Total gestational weight gain (kg) Infant birth weight (g)
Total gestational weight gain (kg) 0.223
Arm girth at trial entry (cm) 20.239 0.046
Arm girth at 36 weeks (cm) 0.002 0.087
Biceps SFTM at trial entry (mm) 20.185 0.009
Biceps SFTM at 36 weeks (mm) 0.070 0.055
Triceps SFTM at trial entry (mm) 20.159 0.036
Triceps SFTM at 36 weeks (mm) 0.111 0.107
Subscapular SFTM at trial entry (mm) 20.221 20.010
Subscapular SFTM at 36 weeks (mm) 0.028 0.057
Percentage BF at trial entry 20.230 0.007
Percentage BF at 36 weeks 0.066 0.081
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limitation of the literature to date. Although there are limitations to
the use of skinfold measurements as an accurate predictor of adipos-
ity, we adhered to a validated protocol, with acceptable reported
interobserver variability (16), allowing comparisons between treat-
ment groups to be made. Use of alternative methods of the assess-
ment of maternal adiposity may have yielded more accurate estimates
of the relative proportions of adipose and lean tissue mass although
these were not considered feasible for use on such a large scale.
It is widely assumed that women deposit adipose tissue during preg-
nancy, with mobilization of peripheral stores as a fuel source for fetal
growth in late gestation and during lactation (29). A number of obser-
vational studies suggest that there is maximal subcutaneous fat accu-
mulation as measured by skinfold thickness, during the second trimes-
ter of pregnancy, followed by a decline in the third trimester as an
indicator of tissue mobilization (17-20). However, these studies have
largely been confined to relatively lean pregnant women, with the
mean reported early pregnancy BMI within the normal range (17-20).
In contrast, description of the subcutaneous accumulation of fat
stores across gestation among women with a BMI of 25 kg/m2 is
less conclusive. Although some suggest that there is a decrease in
the measures of subcutaneous adipose tissue over pregnancy (19),
others have reported relative stability in SFTM, particularly involv-
ing the triceps and subscapular sites (22). However, changes in
SFTM across pregnancy appear to be site specific, with increases in
central adipose tissue deposition reported by some, as measured at
the suprailiac, subscapular (30), and thigh skinfold sites (22). Impor-
tantly, there appears to be considerable interindividual variation,
with pregnant women with high BMI reported to have a greater var-
iation in the change in fat mass over time when compared with
women of normal BMI (31,32). Although we assessed upper body
measures only, our findings are consistent with those reported by
Sidebottom et al. (22), indicating relatively little change in SFTM
and subcutaneous adipose tissue accumulation in the second and
third trimesters of pregnancy. Additional assessment of maternal
SFTM at 28 weeks of gestation may have allowed greater assess-
ment of mobilization of peripheral adipose tissue stores during ges-
tation although it was not considered feasible in the context of this
study, where participant burden was considerable.
Although measured weight gain in nonpregnant individuals is more
closely reflective of adiposity gain, measuring gestational weight
gain in pregnancy is a relatively poor surrogate for maternal adipos-
ity (8), highlighting the considerable variability which exists across
individual women in the composition of that weight gain (11,12).
Among relatively lean pregnant women, subcutaneous measures of
adipose tissue deposition have been demonstrated to correlate poorly
with gestational weight gain (14,22) although this observation is not
universal, with others suggesting a positive association (32,33). Fur-
thermore, measured gains in maternal adipose tissue appear to be
poorly predictive of infant birth weight (32-34), conferring little
advantage over traditional assessment of prepregnancy or early preg-
nancy BMI (14,20), perhaps with the exception of women with low
prepregnancy weight, where there appears to be a negative correla-
tion with low infant birth weight (35,36).
To date, associations between measured maternal adiposity, gesta-
tional weight gain, and infant birth weight among women with a
BMI of 25 kg/m2 have been poorly investigated. Although obser-
vational data indicate women with obesity have greater gain in cen-
tral adiposity (compared with women of normal BMI), there is poor
correlation with infant birth weight (23,24). These findings are con-
sistent with ours. From a metabolic perspective, changes which
occur during pregnancy are highly complex as it is their relationship
to maternal BMI, adiposity gain, gestational weight gain, and infant
birth weight. It is therefore not surprising that although these meas-
ures may be associated with each other, changes in one may not
necessarily correspond to observable or measurable changes in
another.
As we have reported previously, providing antenatal lifestyle advice
among women with a BMI of 25 kg/m2 was associated with an
18% relative risk reduction in infant birth weight of >4 kg (25), an
effect mediated by changes in maternal diet quality and physical
activity (26) despite the fact that both maternal gestational weight
gain (25) and total energy intake during pregnancy (26) did not dif-
fer significantly between the randomized groups. Our intervention
consisted of three face-to-face sessions and three telephone contacts
over the course of pregnancy and was of similar intensity to those
utilized in the previously published studies (37-39). Although
increasing the intensity of the intervention may have been associated
with greater effects on maternal gestational weight gain and, in turn,
maternal SFTM, it was not considered feasible to implement within
current maternity care models. Furthermore, our findings suggest
that focusing attention solely on gestational weight gain, rather than
achievable, albeit modest changes in dietary intake and physical
activity, may reduce important opportunities to significantly impact
clinically relevant infant outcomes (25,28).
Conclusion
As indicated previously, the use of gestational weight gain is a sur-
rogate measure of maternal adiposity (8,9). Although both gesta-
tional weight gain and maternal adiposity as assessed by peripheral
SFTM are relatively simple measures to obtain, they were not
impacted by our antenatal lifestyle intervention. Furthermore, among
women with a BMI of 25 kg/m2, maternal SFTM and measures of
anthropometry correlated poorly with both gestational weight gain
and infant birth weight. Further mechanistic information is required
to elucidate the specific changes in maternal metabolic pathways
over the course of pregnancy and their relationship, if any, to
peripheral measures of adiposity.O
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